Adagene Inc
ADAG
查看详细走势图
1.820USD
-0.010-0.55%
收盘 12/19, 16:00（美东）报价延迟15分钟
107.22M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.55%
5天
+4.00%
1月
+1.11%
6月
-4.21%
今年开始到现在
-8.54%
1年
-11.22%
查看详细走势图
TradingKey Adagene Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Adagene Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
8
位分析师
买入
评级
9.224
目标均价
+363.53%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Adagene Inc亮点
亮点风险
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
业绩增长期
公司处于发展阶段，最新年度总收入103.20K美元
估值合理
公司最新PE估值-3.59，处于3年历史合理位
机构减仓
最新机构持股14.91M股，环比减少11.08%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值0.00
活跃度增加
近期活跃度增加，过去20天平均换手率0.90
Adagene Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Adagene Inc简介
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
公司代码ADAG
公司Adagene Inc
CEOLuo (Peter)
网址https://www.adagene.com/
常见问题
Adagene Inc(ADAG)的当前股价是多少？
Adagene Inc(ADAG)的当前股价是 1.820。
Adagene Inc的股票代码是什么？
Adagene Inc的股票代码是ADAG。
Adagene Inc股票的52周最高点是多少？
Adagene Inc股票的52周最高点是3.160。
Adagene Inc股票的52周最低点是多少？
Adagene Inc股票的52周最低点是1.300。
Adagene Inc的市值是多少？
Adagene Inc的市值是107.22M。
Adagene Inc的净利润是多少？
Adagene Inc的净利润为-33.42M。
现在Adagene Inc(ADAG)的股票是买入、持有还是卖出？
根据分析师评级，Adagene Inc(ADAG)的总体评级为买入，目标价格为9.224。
Adagene Inc(ADAG)股票的每股收益（EPS TTM）是多少
Adagene Inc(ADAG)股票的每股收益（EPS TTM）是-0.515。
相关品种
